Evaluating the heart protection of dapagliflozin in breast cancer patients undergoing chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess whether dapagliflozin can provide cardioprotective effects against cardiotoxicity caused by anthracycline chemotherapy in breast cancer patients. Participants will receive dapagliflozin daily starting one week before their first cycle of anthracyclines and continuing until the last dose. The study will monitor the incidence of cardiotoxicity and any medical issues arising from dapagliflozin use. The trial focuses on patients with invasive breast carcinoma who are eligible for anthracycline treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. patients with pathologically proved invasive breast carcinoma.
2. Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines.
3. Renal function (eGFR \> 30 mL/minute per 1.73 m2 )
4. LVEF is more than 50 %
5. Age ≥ 18 and ≤ 60 years old

Exclusion Criteria:

1. patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction.
2. Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens
3. pregnant or breastfeeding patients
4. patients receiving any other cardiotoxic agents.
5. Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.
6. Mediastinal irradiation including heart.
7. Refusal to sign the written informed consent.

Where it's running

• Al demerdash hospital at oncology departement
  Cairo, Cairo Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Shimaa Nabil Abd elaziz Hassanein, bachelor
• Email: Shimaa.Nabil@pharm.helwan.edu.eg
• Phone: +201115817090

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.